Meridian Bioscience, Inc. (VIVO)

Investigation 

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Meridian Bioscience, Inc. ("Meridian" or "the Company") (NASDAQ: VIVO). The investigation concerns whether Meridian and certain of its officers and/or directors have violated federal securities laws.

 

On February 16, 2021, Meridian issued a press release “provid[ing] an update on its application for Emergency Use Authorization (EUA) with the U.S. Food and Drug Administration (FDA) for the SARS-CoV-2 molecular diagnostic test on its Revogene® platform.”  The press release advised investors that “[i]n its ongoing discussion with the FDA, late in the day on Friday, February 12, 2021, the Company received further correspondence requesting additional information on the SARS-CoV-2 molecular diagnostic test on its Revogene® platform” and “has elected to place shipments of the SARS-CoV-2 test kits on hold while it continues to work with the FDA.”  On this news, Meridian’s stock price fell $3.70 per share, or 12.41%, to close at $26.12 per share on February 16, 2021.

 

If you are aware of any facts relating to this investigation, or purchased Meridian shares, you can assist this investigation by visiting contacting the firm. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

© 2020 Bronstein, Gewirtz & Grossman, LLC

  • Twitter Social Icon
  • LinkedIn

BG&G is not affiliated to any of these companies. All respective trademarks are owned by the respective companies.